Author:
Mitrovski Biserka,Pressacco Josie,Mandelbaum Saul,Erlichman Charles
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference28 articles.
1. Rustum YM, Creaven PJ (1988) Symposium on the expanding role of folates and fluoropyrimidines in cancer chemotherapy. J Natl Cancer Inst 80: 1524?1525
2. Cantwell BM, Macaulay V, Harris AL, Kaye SB, Smith IE, Milsted RA, Calvert AH (1988) Phase II study of the antifolateN10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer. Eur J Cancer Clin Oncol 24: 733?736
3. Harding MJ, Cantwell BM, Milstead RA, Harris AL, Kaye SB (1988) Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer. Br J Cancer 57: 628?629
4. Calvert AH, Newell DR, Jackman AL, Gumbrell LA, Sikora E, Grzelakowska-Sztabert B, Bishop JA, Judson IR, Harland SJ, Harrap KR (1987) Recent preclinical and clinical studies with the thymidylate synthase inhibitorN10-propargyl-5,8-dideazafolic acid (CB 3717). Natl Cancer Inst Monogr 5: 213?218
5. Bassendine MF, Curtin NJ, Loose H, Harris AL, James OF (1987) Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. A phase II study. J Hepatol 4: 349?356
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献